Millennium Management
PTCT icon

Millennium Management’s PTC Therapeutics PTCT Stock Holding History

Millennium Management’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-30,000
Closed -$1.45M – 6576
2023
Q1 		$1.45M Buy
+30,000
New +$1.37M ﹤0.01% 3742
2022
Q3 		– Sell
-10,000
Closed -$401K – 7407
2022
Q2 		$401K Buy
+10,000
New +$351K ﹤0.01% 5128
2016
Q1 		– Sell
-50,000
Closed -$1.62M – 3585
2015
Q4 		$1.62M Sell
50,000
-200,000
-80% -$5.89M ﹤0.01% 2060
2015
Q3 		$6.67M Buy
250,000
+190,000
+317% +$8.13M 0.01% 1168
2015
Q2 		$2.89M Buy
60,000
+10,000
+20% +$583K 0.01% 1706
2015
Q1 		$3.04M Buy
+50,000
New +$3.05M 0.01% 1690

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Millennium Management's PTCT Position: Q1 2026 in Review

Millennium Management sold out of PTC Therapeutics (PTCT) in Q1 2026, closing a stake of 22,494 shares — an estimated $1.71M sold.

Millennium Management first reported a position in PTCT in Q2 2014 and held it in 39 quarters. The position peaked at $64.8M in Q3 2025. 350 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Millennium Management reported no remaining PTC Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Millennium Management sold 22,494 PTC Therapeutics shares in Q1 2026, an estimated $1.71M.
  • Millennium Management first reported a position in PTC Therapeutics in Q2 2014 and held it in 39 quarters.
  • Millennium Management's PTC Therapeutics position peaked at $64.8M in Q3 2025.
  • 350 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.